Buspar for managing generalized anxiety disorder in adults

Buspar (buspirone hydrochloride tablets) is a non-benzodiazepine anxiolytic primarily used to manage anxiety disorders, specifically generalized anxiety disorder (GAD), in adults. It differs from typical sedative anxiolytics by lacking significant sedative, anticonvulsant, or muscle relaxant effects, and it has a distinct mechanism involving serotonin and dopamine receptors.

Buspar is indicated for the management of anxiety disorders or for short-term relief of anxiety symptoms in adults. Its clinical efficacy has been demonstrated mainly in outpatients with generalized anxiety disorder (GAD), including those with mild depressive symptoms concurrent to GAD. It is not intended for anxiety or tension related to everyday stress that does not require anxiolytic treatment.

Long-term safety and effectiveness beyond 3 to 4 weeks have not been established in controlled trials, although use up to one year has been observed without adverse outcomes. Extended use should be regularly reassessed by the prescribing physician.

Buspirone hydrochloride

The exact mechanism of buspirone is not fully understood. It is not chemically related to benzodiazepines and does not bind benzodiazepine receptors or affect GABA binding. Buspirone has a high affinity for serotonin (5-HT1A) receptors and moderate affinity for brain dopamine (D2) receptors, which may contribute to its anxiolytic effects. It does not cause significant sedation or muscle relaxation that are common with other anxiolytics.

The recommended starting dose for adults is 15 mg daily divided into two doses of 7.5 mg. Dosage may be increased by 5 mg every 2 to 3 days as needed to achieve optimal response, not exceeding 60 mg per day. Typical effective doses in clinical trials ranged from 20 mg to 30 mg daily in divided doses.

Buspirone tablets should be taken consistently either always with food or always without food because food significantly increases its bioavailability. Dosage adjustments are necessary when coadministered with potent CYP3A4 inhibitors or inducers, guided by clinical assessment.

Buspirone hydrochloride tablets are contraindicated in patients with known hypersensitivity to buspirone.

Use with monoamine oxidase inhibitors (MAOIs) is contraindicated due to risk of hypertensive reactions.

• Contraindication: Known hypersensitivity to buspirone hydrochloride.
• Precautions with MAOIs: Buspirone should not be used concomitantly with monoamine oxidase inhibitors (MAOIs) due to risk of elevated blood pressure.
• Withdrawal caution: Buspirone does not prevent withdrawal symptoms from benzodiazepines or other sedative-hypnotics; gradual withdrawal from such drugs is advised before starting buspirone.
• CNS effects: While buspirone is less sedating than other anxiolytics, patients should be cautious about driving or operating machinery until individual effects are known.
• Potential dopaminergic effects: Some patients may experience restlessness or akathisia shortly after starting treatment.
• Use in hepatic or renal impairment: Buspirone exposure is significantly increased in patients with severe hepatic or renal impairment; use is not recommended in these populations.

Buspirone is generally less sedating than benzodiazepines and does not cause significant cognitive or motor impairment. Some patients may report dizziness, headache, nausea, or restlessness (including akathisia). No dependence or withdrawal syndromes have been clearly associated with buspirone.

• MAO inhibitors: Concomitant use is contraindicated due to risk of hypertensive episodes.
• CYP3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole, verapamil, diltiazem, nefazodone): Can markedly increase buspirone plasma levels, requiring dose reduction.
• CYP3A4 inducers (e.g., rifampin, dexamethasone, phenytoin, phenobarbital, carbamazepine): Can reduce buspirone levels, possibly requiring dose increase.
• Grapefruit juice: Increases buspirone levels significantly; patients should avoid large amounts.
• Psychotropic drugs: Caution advised; specific interactions noted with amitriptyline, diazepam, haloperidol, trazodone, and flurazepam without significant clinically relevant impact.
• Cimetidine: May increase buspirone peak concentration.
• Potential lab test interference: Buspirone may cause false positive urinary metanephrine/catecholamine tests, so it should be stopped 48 hours before such testing.

Pregnancy: Buspirone is classified as Pregnancy Category B. Animal studies have not shown harm to the fetus at doses up to 30 times the human dose, but adequate human studies are lacking. Use only if clearly needed.

Lactation: Buspirone and its metabolites are excreted in rat milk; human excretion is unknown. Avoid use during breastfeeding if possible.

Specific overdose symptoms and management were not described in the supplied evidence.

Store buspirone hydrochloride tablets at controlled room temperature as per product labeling. Specific storage instructions were not detailed.